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ABSTRACT
Introduction: Common variable
immunodeficiency (CVID) represents a large
heterogeneous group of antibody-deficiency
syndromes associated with a wide range of
clinical features and a lack of defined causes in
the realm of primary immunodeficiencies. Here,
we present a case of CVID in a 62-year-old white
male patient with a history of longstanding
complex regional pain syndrome (CRPS).
Case Presentation: His medical history
included multiple sinus infections per year
and several pneumonias requiring antibiotics.
He has had various back surgeries, including a
laminectomy at the L4 level 1 year prior to his
diagnosis. Thereafter, he underwent four
sympathetic nerve blocks with minimal pain
relief. Blood chemistries showed a normal white
blood cell count with a normal differential, but
increased erythrocyte sedimentation rate and
C-reactive protein levels. Total Ig
(Immunoglobulin)G was 611 mg/dL (normal
700–1,600), IgG1 was 425 mg/dL (341–894),
IgG2 was 114 mg/dL (171–632), IgG3 was
14.4 mg/dL (18.4–106), and IgG4 was 7.4 mg/
dL (2.4–121). IgA was 47 mg/dL (normal
70–400), IgM was 131 mg/dL (40–230), and IgE
was 4.5 kU/L (\4.0). He only had 10 of 23
pneumococcal titers in the protective range
post-vaccination. Upon treatment of the CVID
with intravenous immunoglobulin, the
patient’s pain levels were significantly
decreased and have been maintained for more
than 2 years.
Conclusion: Therefore, immunoglobulin
therapy appears to have been beneficial in the
treatment of the patient’s symptoms of CRPS,
including pain. Additional studies investigating
the mechanism by which immunoglobulin
therapy may reduce the inflammation and
pain of CRPS are needed.
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INTRODUCTION
Complex regional pain syndrome (CRPS) is a
condition characterized by continuing regional
pain that is seemingly disproportionate in the time
or degree to the usual course of pain after trauma or
other lesion [1–3]. Previously called reflex
sympathetic dystrophy (CRPS Type I) or causalgia
(Type II), CRPS occurs with or without definable
nerve lesions, respectively. CRPS typically involves
abnormal sympathetic, sensory, motor,
sudomotor, vasomotor edema, and/or other
trophic findings that may occur after an injury
or surgical procedure, but frequently there is no
ensuing event [1, 3]. Clinical features such as
burning pain with allodynia and hyperalgesia with
changes in skin temperature also occur in the
affected limb.CRPScanstrikeat anyageandaffects
both men and women equally [4].
Common variable immunodeficiency
(CVID) is the most common, symptomatic
primary immunodeficiency [5, 6] and affects 1
in 50,000 to 1 in 75,000 individuals [7]. CVID
can be diagnosed in both children and adults,
and is hallmarked by two low isotypes of
immunoglobulin (i.e., IgG and IgA) along with
low specific antibody response. The disease can
result in serious and recurrent bacterial and
viral infections of the ears, sinuses, nose,
bronchi, and lungs and is associated with
increased frequency of infections, autoimmune
disease, gastrointestinal and pulmonary disease,
hepatitis, lymphoma, and other cancers [5, 7–
10]. Individuals with CVID may not receive a
diagnosis until later in life because the
symptoms of antibody deficiency may not
become obvious until then [5].
Because of the varied illnesses and symptoms
that may appear, individuals with CVID may
receive medical care from physicians in a variety
of clinical specialties often leading to delayed
diagnosis. The following case involves a patient
with an undiagnosed immune deficiency that,
when treated, appeared to help with his original
pain complaint.
CASE PRESENTATION
A 62-year-old white male with a 2-year history
of CRPS of his right lower extremity, without
inciting injury, presented to our immunology
clinic for evaluation. The patient previously
reported symptoms consistent with CRPS
diagnosed by his rheumatologist, including
continuing pain that was disproportionate to
any inciting event, as well as allodynia (to light
touch), edema, and decreased range of motion
and motor dysfunction (e.g., weakness, tremor,
dystonia). He has also been followed by his
rheumatologist for the diagnosis of Sjo¨gren’s
syndrome and Rheumatoid Arthritis. In our
clinic, he described a gripping pain, different
from arthritic pain, from his right knee area to
his ankle that was without any swelling,
pruritus, or dermatitis. The pain was worse in
the anterior region than in the posterior regions
around his knee. Allodynia below the knee was
so severe in that region that he would wear a leg
‘‘tunnel’’ to avoid contact with his blanket at
night. His medical regimen to control the pain
included gabapentin 300 mg 3 times daily,
abatacept 750 mg intravenously weekly, and
hydrocodone/acetaminophen 5/500 mg every
8 h as needed.
The patients’ medical history included
multiple sinus infections per year and 6
lifetime pneumonias requiring antibiotics. He
was hospitalized twice for pneumonia while
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serving in the army. He has had various back
surgeries, including a laminectomy at the L4
level, 1 year prior to his diagnosis. There were
no bony changes on imaging of the lower
extremity. Shortly after the laminectomy, he
underwent 4 sympathetic nerve blocks with
minimal pain relief.
He is retired, denied any illegal drug or alcohol
use, and reported a non-contributory family or
social history. He has no children and his parents
are deceased. On physical examination, his vital
signs were all within the normal range. His gait
was antalgic with a cane, and he was overweight,
with a body mass index of 32. His hair, skin, and
dentition appeared normal with no ulcers in the
oral cavity. Cardiac, pulmonary, and abdominal
examinations were unremarkable. His
extremities were warm and well-perfused,
although he had noticeable tenderness to
palpation of the right shin and knee regions.
The calf measurements were 38 cm at their peak
on both legs. His strength was 4 out of 5 (with a 5
being the maximum strength) in the right knee
and 5 out of 5 on the left; reflexes and joints were
normal without cyanosis or dermatitis.
Blood chemistries included a white blood
cell count of 7.7 K/lL (normal 4–11) with a
normal differential, erythrocyte sedimentation
rate (ESR) was 28 mm/h (normal 0–15), and
C-reactive protein was 1.6 mg/dL (normal\1.0).
Total IgG was 611 mg/dL (normal 700–1,600),
IgG1 was 425 mg/dL (341–894), IgG2 was
114 mg/dL (171–632), IgG3 was 14.4 mg/dL
(18.4–106), and IgG4 was 7.4 mg/dL (2.4–121).
IgA was 47 mg/dL (normal 70–400), IgM was
131 mg/dL (normal 40–230), and IgE was
4.5 kU/L (normal \4.0). A total of 10/23 post-
vaccination, pneumococcal serotype titers were
in the protective range. Complement C4 was
27 mg/dL (normal 14–44). Anti-nuclear
antibodies, as well as, anti-Sm, anti-RNP, anti-
SSA and SSB, anti-Scl70, and anti-Jo1 were all
negative.
Upon diagnosis of CVID, the patient was
started on intravenous immunoglobulin (IVIG)
500 mg/kg monthly. Physical therapy was
begun thereafter, and as little as 1 day after
initial and subsequent infusions, the patient
reported a dramatic decrease in lower extremity
pain. He reported feeling the pain remounting
by the 4th week after each infusion, but overall
this seems to be more tolerated than in the past.
On a 0–10 numeric pain intensity scale (with 10
being the most severe pain), his right leg pain
decreased significantly from 7 out of 10 to 2 out
of 10, and the patient reported a significant
increase in energy. Strength was reported as 5
out of 5 in each knee. Initially, calf
measurements were 37.5 cm on the right and
38 cm on the left. At 1-year follow-up, both
right and left calf measurements were 37 cm.
Informed consent was obtained from the
patient for being included in the study.
DISCUSSION
Common variable immunodeficiency
represents a large heterogeneous group of
antibody-deficiency syndromes associated with
a wide range of clinical features and a lack of
defined causes in the realm of primary
immunodeficiencies. While the benefit of
immunoglobulin replacement to treat CVID is
well-known and current practice guidelines
support the use of subcutaneous or IVIG to
treated patients with CVID, the efficacy of IVIG
in the treatment of inflammation and pain
caused by CRPS is not yet as definitive and
supportive data is limited.
A study by Goebel et al. [11] investigated the
efficacy of IVIG therapy in a small cohort of
patients who had pain intensity greater than 4
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on an 11-point pain scale and had CRPS for
6–30 months refractory to standard treatment.
For the 12 patients who completed the 4-week
trial, IVIG 500 mg/kg significantly reduced the
average pain intensity 1.55 U in comparison
with treatment with saline (P\0.001). In
addition, a total of 3 patients had median pain
scores that were lowered by 50%. Despite
several limitations to the study, including the
trial size, the authors showed that there was a
significant reduction in pain associated with
CRPS as a result of IVIG treatment [12].
In the United States, one indicated use of
IVIG is to relieve pain associated with chronic
inflammatory demyelinating polyneuropathy
[12]. Although the mechanism is not fully
understood and may differ among pain
syndromes, there are also a few pilot studies
and clinical trials that have investigated the use
of IVIG in the treatment of pain associated with
Stiff-Person syndrome [13, 14], post-polio
syndrome [15–17], and refractory neuropathic
pain [18]. A phase 1/2 trial investigating the use
of IVIG in treating acute pain in sickle cell
disease is currently recruiting [19].
Here, we have presented the case of a male
previously diagnosed with CRPS who
subsequently was found to have CVID
diagnosed by a low IgA and IgG and
suboptimal pneumococcal antibody titers
prompted by a history of recurrent sino-
pulmonary bacterial infections. The patient’s
age at time of CVID diagnosis should be noted
as it highlights the matter of diagnostic delay
despite a history of recurrent respiratory
infections. Upon initiation of IVIG therapy
using the immune deficiency dosing (for this
patient 500 mg/kg monthly), the patient’s pain
levels were significantly decreased and have
remained suppressed for more than 2 years. The
patient was also diagnosed with rheumatoid
arthritis and Sjo¨gren’s syndrome by his
rheumatologist, which was not surprising due
the increased prevalence of autoimmune
diseases in CVID patients [8–10, 20]. Since
CRPS is not known to do so, these co-existing
autoimmune diagnoses most likely account for
the elevated inflammatory markers as evidenced
by the increased ESR and C-reactive protein.
In addition, due to the increased incidence
of malignancy in CVID patients [in particular,
gastrointestinal (GI)], the patient was referred to
a GI specialist for the follow-up.
The patient continues physical therapy with
aquatherapy once a week and uses a
transcutaneous electrical nerve stimulation
unit regularly on his leg and back. The pain
level (2 out of 10) for the patient has been
maintained, and from as little as 1 day after
each infusion he has reported a complete
absence of pain. The patient also has had no
bacterial infections since starting IVIG
treatment, feels more energetic, and ambulates
with greater ease.
CONCLUSION
Upon treatment of the CVID with IVIG therapy,
the patient’s pain levels due to CRPS were
significantly decreased and have been
maintained for more than 2 years. Therefore,
immunoglobulin therapy appears to be
beneficial in the treatment of CRPS symptoms,
including pain. When treating patients with
CRPS and signs of immunodeficiencies such as
recurrent sino-pulmonary disease, pain
specialists should work them up with
immunologic laboratory testing, or refer to an
immunologist. Although the treatment for
autoimmune inflammatory conditions respond
to high doses of immunoglobulin therapy
(usually 2 g/kg IV monthly), our patients’
CRPS symptoms have responded to the lower
132 Pain Ther (2013) 2:129–134
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immunodeficiency dose (400–600 mg/kg IV
monthly), according to guidelines used in
treating his CVID. Additional studies
investigating the mechanism by which
immunoglobulin therapy may reduce the
inflammation and pain in CRPS are needed.
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